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Objective: To provide a systematic review of the outcomes of thoracic endovascular aortic repair (TEVAR) for aortoe-
sophageal ﬁstula (AEF) and to identify prognostic factors associated with poor outcomes.
Methods: Literature searches of the Embase, Medline, and Cochrane databases identiﬁed relevant articles reporting results
of TEVAR for AEF. The main outcome measure was the composite of aortic mortality, recurrence of the AEF, and stent
graft explantation. The secondary outcome measure was aortic-related mortality.
Results: Fifty-ﬁve articles were integrated after a literature search identiﬁed 72 patients treated by TEVAR for AEFs. The
technical success rate of TEVARwas 87.3%. The overall 30-daymortality was 19.4%. Prolonged antibiotics (>4weeks) were
administered in 80% of patients. Concomitant or staged resection or repair of the esophagus was performed in 44.4% of
patients. Stent graft explantationwas performedwithin the ﬁrst month after TEVAR as a planned treatment in 11.1%. After
a mean follow-up of 7.4 months (range, 1-33 months), the all-cause mortality was 40.2%, and the aortic-related mortality
was 33.3. Prolonged antibiotic treatment (P[ .001) and repair of AEFs due to a foreign body (P[ .038) were associated
with a signiﬁcant lower aortic mortality. On univariate analysis, TEVAR and concomitant or staged adjunctive procedures
(resection, repair of the esophagus, or a planned stent graft explantation) were associated with a signiﬁcantly lower inci-
dence of aortic-related mortality (P[ .0121). When entered into a binary logistic regression analysis, prolonged antibiotic
treatment was the only factor associated with a signiﬁcant lower incidence of the endpoint (P[ .003).
Conclusions: Late infection or recurrence of the AEF and associated mortality rates are high when TEVAR is used as a sole
therapeutic strategy. Prolonged antibiotic treatment has a strong negative association with mortality. A strategy of
a temporizing endovascular procedure to stabilize the patient in extremis, and upon recovery, an open surgical esophageal
repair with or without stent graft explantation is advocated. (J Vasc Surg 2014;59:248-54.)Primary and secondary aortoesophageal ﬁstulas (AEFs)
are uniformly fatal if untreated and remain a formidable
surgical problem in older, high-risk patients with hemor-
rhagic shock or sepsis. Despite advances in surgical tech-
nique, open repair still has a high operative mortality,
which may reach 55.5% even in centers of excellence.1 The
mortality and morbidity of open repair is multifactorial:
 Emergent nature of repair;
 Difﬁcult access to the aorta, high risk of visceral injury,
and signiﬁcant blood loss because of dense adhesions
and mediastinitis; and
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Thoracic endovascular aortic repair (TEVAR) has
recently gained popularity as an emergent treatment for
AEFs, despite the high risk of infection. Reports often
feature favorable short-term outcomes. Although endovas-
cular stent grafting is faster and safer than surgery in
unstable patients, the major concern is the durability of
this approach. TEVAR does nothing to address the issue
of the defect in the digestive tract, leaving the patients at
risk of AEF recurrence and/or stent graft infection.
The aim of this article is to deﬁne the outcomes of
TEVAR for AEFs with a particular focus on midterm
results and to determine the prognostic factors associated
with poor outcomes.METHODS
Search strategy. A systematic review was performed
using the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis guidelines.2 A literature
search was undertaken to identify all published studies in
the past 10 years reporting TEVAR for AEFs. Candidate
Table I. Case selection, clinical presentation, and causes of aortobronchial ﬁstulas
Alive Dead P value
No. 48 24
Mean age, years 58 62 .516
Male gender, % 68.8 61.1 .686
Initial presentation Hematemesis 91.6% (44/48) 75% (18/24) .267
Hypovolemic shock 56.5% (26/46) 72.2% (13/18) .446
Systemic infection 22.9% (11/48) 23.8% (5/21) .321
Cause of aortobronchial ﬁstula Previous thoracic aortic surgery 16.6% (8/48) 16.6% (4/24) .487
Previous TEVAR 2 % (1/48) 8.3 % (2/24) .108
Benign esophageal disease 12.5% (6/48) 12.5% (3/24) .761
Malignant esophageal disease 12.5% (6/48) 8.3 % (2/24) .784
Thoracic aortic aneurysm 25% (12/48) 12.5% (3/24) .574
Aortic dissection 4.1% (2/48) 4.1 % (1/24) .792
Penetrating ulcer 8.2% (4/48) 4.1 % (1/24) .732
Mycotic aneurysm 4.1% (2/48) 12.5% (3/24) .222
False aneurysm 22.9% (11/48) 8.3 % (2/24) .411
Foreign body 18.7% (9/48) 0% (0/24) .038
TEVAR within 24 hours of diagnosis 83.3% (40/48) 83.3% (20/24) .684
Antibiotic therapy >4 weeks 94.4% (34/36) 42.8% (6/14) .001
TEVAR, Thoracic endovascular aortic repair.
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Embase, Medline, and Cochrane databases for the period
of 1990 to January 2013. Key words entered in this search
were “thoracic aorta,” “aortoesophageal,” “aorto-esopha-
geal,” or “esophagus.” Articles were limited to those
published in the English language. Additionally, manual
evaluation of the reference lists of the retrieved articles, and
reviews on this ﬁeld were undertaken.
Study selection. Studies were considered for inclusion
on the basis of the following criteria:
 Reporting on TEVAR for management of AEF; and
 Reporting on clinical outcome.
Studies containing duplicate data were excluded, and
the manuscripts with the most recent or the best-
documented material from the same authors were used
for analysis. Articles were selected for further review and
inclusion in the ﬁnal analysis if they described individual
outcomes for patients treated for AEFs.
Data extraction. Data were extracted regarding age
and gender; cause of ﬁstula; presence and/or history of
thoracic aortic surgery; time interval between previous
aortic intervention and presentation of ﬁstula; comorbidity;
symptoms of the ﬁstula; time interval between diagnosis
and TEVAR; proximal landing zone; technical success of
TEVAR deﬁned by successful exclusion of the ﬁstula
during the initial endovascular procedure; concomitant or
staged resection or repair or exclusion or stenting of the
esophagus; stent graft explantation and resection or repair
of the esophagus within the ﬁrst month after TEVAR as
a planned treatment; antibiotic usage and duration; in-
hospital and long-term follow-up outcomes, including
graft-related complications (endoleak, stent graft migra-
tion); nongraft-related complications (sepsis, pneumonia,
spinal cord ischemia, renal failure), early and late open andendovascular reinterventions; ﬁstula recurrence; ﬁstula-
related mortality; and length of follow-up.
Statistical analysis. The primary outcome of interest
was the composite of aortic mortality, recurrence of the
AEF, and stent graft explantation. The secondary outcome
measure was aortic-related mortality.
Patients included were classiﬁed according to the
surgical strategy to assess whether TEVAR and resection
or repair of the esophagus or planned stent graft explanta-
tion and resection or repair of the esophagus was associated
with a lower mortality rather than TEVAR alone. If the
initial strategy was not clearly mentioned, patients were
included in the single-stage group.
Statistical analysis was performed using SPSS (SPSS
Inc, Chicago, Ill). c2, Fisher exact, and independent
samples t-tests were performed for the univariate analysis.
Binary logistic regression was utilized to identify factors
that were independently associated with each of the
outcomes of interest. All results with P < .05 were consid-
ered statistically signiﬁcant.
RESULTS
Search results. Fifty-ﬁve articles were integrated after
a literature search identiﬁed 72 patients treated by TEVAR
for AEFs.2-56
Case selection. Patient demographics, presenting
features, and comorbidities are shown in Tables I and II.
The mean age was 59.2 years, and 67.7% were male. Most
patients presented with hematemesis (86.1%). Hypo-
volemic shock and systemic infection were present in 60.9%
and 21.7%, respectively. With regard to etiology, 23.6% of
the patients had primary disease of the esophagus (malig-
nant or benign), 20.8% of the patients had previously
undergone thoracic aortic surgery (open or endovascular
repair), 20.8% of the patients had aneurysm of the
descending aorta, and 12.5% of the patients had ﬁstula
Table II. Case selection, clinical presentation, and causes of aortoesophageal ﬁstulas (AEFs)
TEVAR alone Combined: TEVAR and surgery P value
No. 40 32
Mean age, years 64 55 .001
Male gender, % 53.3 81.2 .051
Initial presentation Hematemesis 87.5% (35/40) 84.3% (27/32) .53
Hypovolemic shock 67.6% (23/34) 53.3% (16/30) .251
Systemic infection 35.1% (13/37) 9.3% (3/32) .011
Cause of AEF Previous thoracic aortic surgery 22.5% (9/40) 9.3% (3/32) .121
Previous TEVAR 2.5% (1/40) 6.2% (2/32) .22
Benign esophageal disease 12.5% (5/40) 12.5% (4/32) .438
Malignant esophageal disease 12.5% (5/40) 9.3% (3/32) .388
Thoracic aortic aneurysm 12.5% (5/40) 31.2% (10/32) .08
Aortic dissection 2.5% (1/40) 6.2% (2/32) .332
Penetrating ulcer 7.5% (3/40) 6.2% (2/32) .424
Mycotic aneurysm 10% (4/40) 3.1% (1/32) .214
False aneurysm 22.5% (9/40) 12.5% (4/32) .213
Foreign body 7.5% (3/40) 18.7% (6/32) .134
TEVAR within 24 hours of diagnosis 82.5% (33/40) 84.3% (27/32) .372
Antibiotic therapy >4 weeks 72.4% (21/29) 90.4% (19/21) .357
TEVAR, Thoracic endovascular aortic repair.
Combined TEVAR and surgery includes: patients treated by TEVAR with concomitant or staged resection or repair or exclusion or stenting of the esophagus;
patients treated by TEVAR with stent graft explantation and resection or repair of the esophagus, which was performed within the ﬁrst month after TEVAR as
a planned treatment.
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ported in 43.2% of the cases (32/74) and isolated in 31.2%
(10/32), and included enterococcus species, mycobacte-
rium tuberculosis, streptococcus spp, or gram-negative
species.
Endovascular repair. TEVAR was performed within
24 hours following diagnosis in 83.3% of the patients.
The technical success rate was 87.3%. The proximal
landing zone was zone 2 in 21.1% of the patients, zone 3
in 46.4% of the patients, and zone 4 in 32.5% of the
patients. A total of 44.4% (32/72) of patients had concom-
itant or staged adjunctive procedures, which included
resection, repair, exclusion, or stenting of the esophagus.
Stent graft explantation and resection or repair of the
esophagus was performed within the ﬁrst month after
TEVAR as a planned treatment in 11.1% of the patients.
Prolonged postoperative antibiotics (greater than 4 weeks)
were administered to 80% of patients.
Perioperative outcomes. As shown in Table III,
perioperative outcomes were deﬁned as those occurring
within the ﬁrst 30 postoperative days. The overall 30-day
mortality was 19.4% (14/72). The early morbidity rate
was 40.2% (29/72). Persistent postoperative sepsis was the
most common early complication (23.6%). The incidence
of aortic rupture, pulmonary complication, multiorgan
failure, endoleak, and recurrent hematemesis was 5.5%
(4/72), 6.9% (5/72), 6.9% (5/72), 9.7% (7/72), and
5.5% (4/72), respectively. Only one case of paraplegia was
observed (Table III).
Midterm outcomes. Midterm outcomes were deﬁned
as those occurring after 30 days. After a mean follow-up of
7.4 months (range, 1-33 months), the all-cause mortality
rate was 40.2% (29/72) and the aortic-related mortalitywas 33.3% (24/72). The death was due to stent graft
infection in 11 patients and to the recurrence of the AEF in
10 patients. Surgical conversion during the postoperative
course with thoracic stent graft explantation was required
in four patients.
Statistical analysis. Univariate analysis demonstrated
that prolonged antibiotic treatment (>4 weeks; P ¼
.001) and repair of an AEF due to a foreign body (P ¼
.038) were associated with a signiﬁcantly lower incidence
of the composite end point (Table I). When entered into
a binary logistic regression analysis, prolonged antibiotic
treatment was the only factor associated with a signiﬁcant
lower incidence of the end point (odds ratio, 0.3; 95%
conﬁdence interval, 0.001-0.21; P ¼ .003; Table IV).
Patients in the two groups, TEVAR alone and TEVAR
combined open repair, were statistically comparable, except
for the mean age of the patients. Patients were younger
in the combined group (55 vs 64 years old; P ¼ .001;
Table II). Univariate analysis demonstrated that a combined
procedure (TEVAR with concomitant adjunctive proce-
dures) was associated with signiﬁcant lower aortic-related
mortality (40% vs 15.6%; P ¼ .036), but this failed to reach
statistical signiﬁcance when entered into a binary logistic
regression (P ¼ .62).
The type of device was available in 83.3% of the cases
(60/72). A Dacron graft was used in 66.6% of the cases
(40/60), and a PTFE graft was used in 33.4% of the cases
(20/60). Rate of infection was not statistically different in
the two groups (7 vs 4; P ¼ .456).
DISCUSSION
AEF is a rare complication, and is generally fatal
without surgical intervention. Causes for AEF formation
Table IV. Logistic regression model
Variable OR 95% CI P value
Outcome composite end point
Combined procedure: TEVAR
and surgery
1.03 0.19-5.40 .96784
Antibiotic therapy >4 weeks 0.03 0.001-0.21 .00389
Foreign body 0.22 0.005-2.57 .31503
Outcome aortic-related mortality
Combined procedure: TEVAR
and surgery
0.63 0.077-3.79 .62
Antibiotic therapy >4 weeks <0.001 <0.001->100 .994
Foreign body <0.001 <0.001->100 .993
CI, Conﬁdence interval; OR, odds ratio; TEVAR, thoracic endovascular
aortic repair.
Table III. Case selection, surgical management, and outcomes of the patients
TEVAR alone Combined: TEVAR and surgery P value
No. 40 32
Additional procedure Intercostal muscle ﬂap 0 9.3% (3/32)
Esophagus resection or repair 0 68.7% (22/32)
Esophagus stenting 0 18.7% (6/32)
Surgical conversion 0 25% (8/32)
In-hospital complications Sepsis 20% (8/40) 28.1% (9/32) .504
Hematemesis 7.5% (3/40) 3.1% (1/32) .624
Multiorgan failure 12.5% (5/40) 0% (0/32) .061
Pulmonary complications 2.5% (1/40) 12.5% (4/32) .164
Renal failure 0% (0/40) 6.2% (2/32) .194
Spinal cord ischemia 0% (0/40) 3.1% (1/32) .444
Myocardial infraction 7.5% (3/40) 3.1% (1/32) 1
Endoleak 7.5% (3/40) 12.5% (4/32) .082
Aortic rupture 7.5% (3/40) 3.1% (1/32) .373
Morbidity <30 days 37.5% (15/40) 43.7% (14/32) .429
Mortality <30 days 27.5% (11/40) 9.4% (3/32) .074
Mean follow-up, months 6.9 8.1
Overall mortality 52.5% (21/40) 25% (8/32) .029
Aortic-related mortality 40% (16/40) 15.6% (8/32) .036
Cause of death Stent graft infection 20% (8/40) 9.4% (3/32) .495
Recurrence of ﬁstula 20% (8/40) 6.2% (2/32) .282
Recurrence of ﬁstula 20% (8/40) 6.2% (2/32) .529
Additional procedure Esophagus resection 2.5 % (1/40) 21.8% (7/32) .019
TEVAR 0% (0/40) 3.1% (1/32) .194
Surgical conversion >30 days 2.5 % (1/40) 9.3% (3/32) .228
TEVAR, Thoracic endovascular aortic repair.
Combined TEVAR and surgery includes: patients treated by TEVAR with concomitant or staged resection or repair or exclusion or stenting of the esophagus;
patients treated by TEVAR with stent graft explantation and resection or repair of the esophagus, which was performed within the ﬁrst month after TEVAR as
a planned treatment.
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advanced esophageal cancer, and surgical procedures
involving the aorta and esophagus.
Open repair involves combined replacement or bypass
of the thoracic aorta with concomitant resection or repair
of the involved esophagus. Despite signiﬁcant reﬁnement
in surgical techniques, the operative mortality of open
AEF repair ranges from 45.4% to 55%.1,57 The mortality
and morbidity of open repair is related to the emergent
nature of repair, the access to the aorta in an infected ﬁeld
with a high risk of visceral injury, and signiﬁcant blood loss,
as well as the need for thoracic aortic cross-clamping.The less invasive endovascular strategies enable rapid
control of bleeding and increase the likelihood of postoper-
ative survival. Indeed, the literature shows that endovascu-
lar repair of primary AEF is successful at controlling
bleeding. The perioperative outcomes of the endovascular
approach are associated with a high technical success rate
(87.3%) and more favorable 30-day mortality rate
(19.7%). TEVAR facilitates hemodynamic stabilization by
hemorrhage control in the acute setting, and therefore
reduces the morbidity and mortality associated with an
open repair under these circumstances.
Even if associated with favorable perioperative out-
comes, concerns regarding the durability of TEVAR even
in the short-term are broadly realistic. TEVAR alone leaves
the esophageal defect untreated. The stent graft is directly
exposed to a contaminated environment and ongoing
infection. Therefore, this minimally invasive approach
incurs a risk of stent graft infection and/or ﬁstula recur-
rence and persistent mediastinitis and sepsis. In this review,
the recurrence of the AEF and stent graft infection
occurred in 13.8% and 15.2% of the patients, respectively.
Antibiotic treatment was the only strongly signiﬁcant
factor associated with a lower aortic mortality rate in the
multivariate analysis. Therefore antibiotic treatment should
be applied after endovascular stent placement to correct
and potentially prevent thoracic stent graft infection. Post-
operative antibiotic strategies differed widely among the
various authors, both with regard to the choice of
JOURNAL OF VASCULAR SURGERY
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spectrum antibiotics, including antifungal coverage, are
appropriate initially. Similar to the treatment of abdominal
aortic graft infection, one could argue for a 6- to 8-week
course of broad-spectrum intravenous antibiotics followed
by life-long oral antibiotic suppression for those treated
by TEVAR alone. Some physicians insist that life-long
treatment with oral suppressive antibiotics is required,
while others claim that such treatment can be discontinued
provided there is no clinical, bacteriological, or radiological
evidence of ongoing sepsis.58,59 A conservative policy for
antibiotic treatment might involve at least 4 weeks of peri-
procedural intravenous antibiotics followed by case-speciﬁc
administration of oral suppressive antibiotics according to
clinical and laboratory parameters of infection.
In the univariate analysis, combined immediate or
staged procedures were also signiﬁcantly associated with
a decrease in the aortic-related mortality rate. Several
surgical options have been proposed to decrease the rate
of aortoesophageal recurrence. Topel et al31 suggest that
TEVAR should be considered as a bridge therapy followed
by a delayed durable open repair when the patient has been
stabilized. The advantage of this combined approach is to
address the two essential aims of the surgical procedure.
First, TEVAR allows minimally invasive and rapid control
of the bleeding. Second, the open surgical procedure
allows surgical debridement of the infected mediastinum
with reconstruction of the aortic wall and repair of the
esophageal defect. Staging the repair to allow adequate
nutritional replenishment is likely to improve the outcome
of the deﬁnitive repair. Primary repair with direct suture or
patch of the esophageal erosion is possible only in selected
cases of small esophageal defects without gross contamina-
tion of the mediastinum. Otherwise, esophageal resection
should be considered the treatment of choice in the
management of an esophageal defect in most patients
with AEFs. However, this ideal approach is associated
with a high mortality rate (25%) and a high morbidity
rate (25% of spinal cord ischemia and of persistent renal
failure).
An alternative staged strategy, as reported by Marone
et al,4 is to address the esophageal defect after a planned
interval to prevent secondary stent graft infection, recur-
rence of the ﬁstula, mediastinitis, and death. The aim of
this approach is to treat the esophageal lesions when the
patient is in a more stable condition. The adjunctive proce-
dure may entail primary repair or resection of the esoph-
agus with coverage of the stent graft using muscle or
pleural ﬂaps. Pleural or pericardial ﬂaps, intercostal or ser-
ratus muscle, or omentum can be used to cover the graft.
In their experience, the mortality rate was lower in cases
that involved a combined approach, as compared with
those that involved TEVAR alone. Therefore, a planned
second-stage open operation leaving the stent graft in place
and treating the esophageal condition along with wide
mediastinal drainage, is another therapeutic strategy for
the treatment of patients with AEFs. A multicenter survey
conducted in Italy yielded information on 14 AEFs thatwere treated with TEVAR. The study showed that patients
who undergo combined treatment (TEVAR and esopha-
geal repair) may have lower graft infection rates and better
survival rates than patients who undergo TEVAR alone.
However, the difference in early and late outcome did
not reach statistical signiﬁcance, possibly due to the small
sample size.
The extent of inﬂammation/injury at presentation was
also an important factor affecting outcomes. Patients
treated for AEFs due to a foreign body, who have less
extensive esophageal injury, had statistically better
outcomes (P ¼ .038).
Clearly, any strategy in this patient population needs to
be highly individualized, given the risks of major thoracic
aortic surgery often in a hostile operative ﬁeld. After
controlling the bleeding by TEVAR, the patient should
receive intensive medical support to correct anemia,
broad-spectrum antibiotics, including antifungal coverage,
and adequate nutritional replenishment. There is clearly
no ideal amount of staging time to improve nutrition.
Time between the two stages has to be determined accord-
ing to markers of malnutrition such as weight loss history,
subjective global assessment, and transport protein (album,
alpha-fetoprotein, vitamin D-binding protein). There is,
obviously, risk that the patient never returns for stage 2.
Once the patient has clinically improved, the patient should
be referred to undergo open surgery as soon as possible. In
moribund patients, TEVAR alone can be proposed, as the
risk of recurrence of the ﬁstula or of stent graft infection is
not consistent. In the case of gross infection (eg, sepsis)
and critical physical condition, endovascular treatment
can be performed as bridging therapy until the patient is
sufﬁciently hemodynamically stable to undergo open
surgery: drainage and primary repair or resection of the
esophagus alone or combined removal of the stent graft
and aortic reconstruction. The choice of conduit and route
for aortic reconstruction, and the speciﬁc treatment of the
ﬁstula are dependent on patient age and comorbid condi-
tions and the size of esophageal defect.
Although the present study reported perioperative and
short-term outcomes of TEVAR for AEFs, it has several
limitations. Acknowledged limitations of this systematic
review included the lack of uniformity reporting isolated
microorganism, antibiotic protocol used, devices used
and proximal landing zone, the initial strategy (planned
vs unplanned two-stage approach), and the extent of
inﬂammation/injury at presentation. Furthermore, data
were obtained from case reports and case series with likely
publication bias. Due to the small incidence of this disease,
it is unlikely there will be a planned prospective random-
ized study. However, a large prospective registry could
help to establish the precise beneﬁts of TEVAR and the
eventual need for a staged approach.
CONCLUSIONS
TEVAR for AEFs achieves the primary goal of therapy
(ie, control of bleeding, preventing fatal exsanguination).
The high rate of secondary stent graft infection or
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 1 Canaud et al 253recurrence of the AEF clearly prove that even combined
with broad-spectrum antibiotics, TEVAR cannot replace
surgical debridement and/or drainage of the infected
mediastinum. Whether this is best achieved by drainage
and primary repair/resection of the esophagus alone with
or without removal of the stent graft remains to be proven.
However, prolonged antibiotic treatment has a strong
negative association with mortality.AUTHOR CONTRIBUTIONS
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